Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ERY
|
|||
| Former ID |
DNCL001731
|
|||
| Drug Name |
BMS-394136
|
|||
| Indication | Arrhythmia [ICD-11: BC9Z; ICD-9: 427] | Phase 1 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated potassium channel Kv1.5 (KCNA5) | Target Info | Modulator | [2] |
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Voltage gated Potassium channels | |||
| WikiPathways | Potassium Channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00162448) A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.